# OnCo record ras-on-tri-complex-inhibitors (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/ras-on-tri-complex-inhibitors/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "ras-on-tri-complex-inhibitors" ;
  schema:name "RAS(ON) tri-complex inhibitors"@en ;
  schema:alternateName "Tri-complex inhibitors"@en, "Tricomplex inhibitors"@en, "RAS(ON) inhibitors"@en, "RAS-GTP inhibitors"@en, "Cyclophilin A tri-complex inhibitors"@en ;
  schema:description "Drugs that block RAS, the growth switch stuck on in many cancers, by an indirect route. The drug first attaches to cyclophilin A, a common protein inside cells, and the pair then clamps onto RAS while it is switched on, so RAS can no longer pass its signal along. Daraxonrasib, approved in the United States in 2026 for pancreatic cancer, works this way; others are in trials."@en ;
  schema:url <https://onco.cc/technologies/ras-on-tri-complex-inhibitors/> ;
  schema:dateModified "2026-11-18"^^xsd:date ;
  schema:citation <https://doi.org/10.1126/science.adg9652>, <https://doi.org/10.1038/s41586-024-07205-6>, <https://doi.org/10.1158/2159-8290.CD-24-0027>, <https://doi.org/10.1021/acs.jmedchem.4c02314>, <https://doi.org/10.1021/acs.jmedchem.4c02313>, <https://doi.org/10.1126/science.ads0239>, <https://doi.org/10.1056/NEJMoa2605555>, <https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220910Orig1s000lbl.pdf> ;
  onco:status "approved" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/nsclc/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/kras-inhibitors/>, <https://onco.cc/technologies/molecular-glue-platforms/> ;
  onco:targets <https://onco.cc/targets/kras/> ;
  onco:drugs <https://onco.cc/drugs/daraxonrasib/>, <https://onco.cc/drugs/zoldonrasib/>, <https://onco.cc/drugs/elironrasib/> ;
  onco:companies <https://onco.cc/companies/revolution-medicines/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/> ;
  onco:terms <https://onco.cc/terms/kras-mutation-subtypes/> ;
  onco:trials <https://onco.cc/trials/rasolute-302/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-holderfield-ras-on-multi-selective-inhibitor-nature-2024/>, <https://onco.cc/key-papers/paper-daraxonrasib-pancreatic-n-engl-j-med-2026/> .
